Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback